Am J Perinatol 2021; 38(S 01): e123-e128
DOI: 10.1055/s-0040-1708805
Original Article

Transcervical Foley Balloon Plus Vaginal Misoprostol versus Vaginal Misoprostol Alone for Cervical Ripening in Nulliparous Obese Women: A Multicenter, Randomized, Comparative-Effectiveness Trial

Oscar A. Viteri
1   Department of Obstetrics and Gynecology, University of South Dakota Sanford School of Medicine, Vermillion, South Dakota
2   Avera Medical Group Maternal-Fetal Medicine, Sioux Falls, South Dakota
,
Kareem K. Tabsh
3   Department of Obstetrics and Gynecology, Kern Medical Center, Bakersfield, California
4   Department of Obstetrics and Gynecology, University of Arizona College of Medicine, Tucson, Arizona
,
Mesk A. Alrais
5   Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at The University of Texas Health Science Center at Houston (UT Health), Houston, Texas
,
Ximena C. Salazar
5   Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at The University of Texas Health Science Center at Houston (UT Health), Houston, Texas
,
Juan M. Lopez
3   Department of Obstetrics and Gynecology, Kern Medical Center, Bakersfield, California
,
Randolph Y. Fok
3   Department of Obstetrics and Gynecology, Kern Medical Center, Bakersfield, California
,
Suneet P. Chauhan
5   Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at The University of Texas Health Science Center at Houston (UT Health), Houston, Texas
,
Baha M. Sibai
5   Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at The University of Texas Health Science Center at Houston (UT Health), Houston, Texas
› Author Affiliations

Abstract

Objective Nulliparous obese women are at increased risk of labor induction and cesarean delivery (CD). We sought to determine whether the combination of a transvaginal Foley balloon plus misoprostol prostaglandin E1 (PGE1) is superior to misoprostol alone in reducing the risk for CD.

Study Design We undertook a multicenter, open-label, comparative-effectiveness randomized clinical trial of nulliparous obese women with unfavorable cervix (Bishop's score ≤ 6) undergoing labor induction from January 2016 to June 2018 at three tertiary centers. Those at <32 weeks' gestation, premature rupture of membranes, stillbirth, and major fetal anomalies were excluded. Women were randomized 1:1 to either a combination of Foley balloon and misoprostol or misoprostol alone. Once Bishop's score was >6, further management was deferred to treating physicians. Primary outcome was the rate of CD. Secondary maternal outcomes included duration of induction-to-delivery interval, occurrence of tachysystole, clinical chorioamnionitis, need for operative vaginal delivery, as well as a composite of maternal morbidity (postpartum endometritis, surgical-site infection, venous thromboembolism, need for transfusion, intensive care unit admission, and maternal death). Secondary neonatal outcomes included need for neonatal intensive care unit admission, transient tachypnea of the newborn, respiratory distress syndrome, meconium aspiration syndrome, culture-proven sepsis, neonatal seizures, and a composite of neonatal morbidity (Apgar's score ≤ 7 at 5 minutes, umbilical artery cord pH ≤ 7.10, birth injury, perinatal death). With the rate of CD rate being 53% at Children's Memorial Herman Hospital among nulliparous obese women who underwent induction of labor at ≥32 weeks and met our inclusion criteria; 250 women (125 women per group) were required to answer the study question. All analyses were by intention to treat.

Results Of the 236 women randomized, 113 (48%) were allocated to group 1 (combined Foley and PGE1) and 123 (52%) to group 2 (PGE1 alone). The rate of CD was similar between the groups (45 vs. 43%, p = 0.84, relative risk [RR]: 1.03, 95% CI: 0.75–1.42). There was no difference in the occurrence of tachysystole that resulted in fetal heart rate abnormalities between the groups (8.8 vs. 16.2%, p = 0.09, RR: 0.54, 95% CI: 0.27–1.11). The total duration of the induction-to-delivery interval was also similar between the groups (24.8 ± 13.8 vs. 24.5 ± 14.0 hours, p = 0.87) regardless of the mode of delivery. No differences were seen in the indications for CD and secondary maternal or neonatal outcomes.

Conclusion In this trial of nulliparous obese women undergoing labor induction, cervical ripening with combined Foley balloon and PGE1 resulted in similar CD rates than ripening with vaginal PGE1 alone.

Key Points

  • Nulliparous obese women are at increased risk for cesarean delivery.

  • Combined intravaginal misoprostol-Foley balloon versus misoprostol alone resulted in similar rates of cesarean delivery.

  • Further research is warranted to determine the optimal cervical ripening strategy in this population.

Note

This study was presented in oral format at the at the Society for Maternal-Fetal Medicine 39th Annual Meeting. Las Vegas, NV 2019.


Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT02639429 (protocol available); Trial ID: NCT02639429.




Publication History

Received: 23 September 2019

Accepted: 13 February 2020

Article published online:
16 April 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2012. Natl Vital Stat Rep 2013; 62 (03) 1-20
  • 2 Robinson HE, O'Connell CM, Joseph KS, McLeod NL. Maternal outcomes in pregnancies complicated by obesity. Obstet Gynecol 2005; 106 (06) 1357-1364
  • 3 Olesen AW, Westergaard JG, Olsen J. Prenatal risk indicators of a prolonged pregnancy. The Danish birth cohort 1998-2001. Acta Obstet Gynecol Scand 2006; 85 (11) 1338-1341
  • 4 Vahratian A, Zhang J, Troendle JF, Savitz DA, Siega-Riz AM. Maternal prepregnancy overweight and obesity and the pattern of labor progression in term nulliparous women. Obstet Gynecol 2004; 104 (5 Pt 1): 943-951
  • 5 Buhimschi CS, Buhimschi IA, Malinow AM, Weiner CP. Intrauterine pressure during the second stage of labor in obese women. Obstet Gynecol 2004; 103 (02) 225-230
  • 6 Zhang J, Bricker L, Wray S, Quenby S. Poor uterine contractility in obese women. BJOG 2007; 114 (03) 343-348
  • 7 Pevzner L, Rayburn WF, Rumney P, Wing DA. Factors predicting successful labor induction with dinoprostone and misoprostol vaginal inserts. Obstet Gynecol 2009; 114 (2 Pt 1): 261-267
  • 8 Gauthier T, Mazeau S, Dalmay F. et al. Obesity and cervical ripening failure risk. J Matern Fetal Neonatal Med 2012; 25 (03) 304-307
  • 9 Wolfe KB, Rossi RA, Warshak CR. The effect of maternal obesity on the rate of failed induction of labor. Am J Obstet Gynecol 2011; 205 (02) 128.e1-128.e7
  • 10 World Health Organization. WHO Recommendations for Induction of Labor, 2011. Accessed February 28, 2020 at: https://apps.who.int/iris/bitstream/handle/10665/277233/9789241550413-eng.pdf
  • 11 ACOG Committee on Practice Bulletins -- Obstetrics. ACOG practice bulletin no. 107: induction of labor. Obstet Gynecol 2009; 114 (2 Pt 1): 386-397
  • 12 Wray S. Insights into the uterus. Exp Physiol 2007; 92 (04) 621-631
  • 13 American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 106: intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009; 114 (01) 192-202
  • 14 Tita ATN, Andrews WW. Diagnosis and management of clinical chorioamnionitis. Clin Perinatol 2010; 37 (02) 339-354
  • 15 Viteri OA, Sibai BM. Challenges and limitations of clinical trials on labor induction: a review of the literature. AJP Rep 2018; 8 (04) e365-e378
  • 16 Grobman WA, Rice MM, Reddy UM. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. Labor induction versus expectant management in low-risk nulliparous women. N Engl J Med 2018; 379 (06) 513-523